Psychedelics
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (“Mindset“), a drug discovery and development company focused on developing novel next generation psilocybin-inspired medicines and related technologies, is pleased to announce it has selected a subset of representative compounds belonging to its proprietary third family of patent-pending next generation psychedelic compounds to move into in vivo Proof-of-Concept […]
Psyence Group Inc. (“Psyence”) is pleased to announce that it has concluded its first cultivation and harvest cycle of natural medical psilocybin mushrooms. The mushrooms were grown, harvested, processed, and packed at its premium production facility in Lesotho which has been designed and built to the highest international standards. Jody Aufrichtig, Chief Executive Officer and […]
/ Novamind Inc. (CSE:NM) (“Novamind”), a mental health company specialized in psychedelic medicine, today announced that it will present at Canaccord Genuity’s “New Paradigms & Treatment Approaches in Mental Health” conference on February 3rd and 4th, 2021. The two-day virtual conference will explore the science, intellectual property, and legality of psychedelic compounds, which are at […]
Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts
Numinus Wellness Inc. (“Numinus”) (TSXV: NUMI), a health care and research company developing and delivering psychedelic-centred solutions to treat mental illness, substance abuse and trauma, today announced its financial results for the first quarter for the three months ended November 20, 2020 (“Q1 2021”). After achieving two industry firsts, launching new compassionate access trials, and […]
VANCOUVER, BC, Feb. 1, 2021 /CNW/ – Delic Holdings Corp. (“DELIC” or the “Company“) (CSE: DELC) (OTCQX: DELCF), a psychedelic wellness-focused company, is pleased to announce that Matt Stang has been appointed as the Company’s new Chairman and Chief Executive Officer, effective January 29, 2021. Jackee Stang has resigned as Chief Executive Officer of the Company but will continue to serve the […]
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled: “Facilitating extinction of fear with psilocybin: Model development of biomarkers and mechanisms,” […]
Novamind Reaches Major Milestones for Ketamine and Spravato(TM) Treatments
Novamind Inc. (CSE:NM) (“Novamind”), a leading mental health company specialized in psychedelic medicine, is proud to announce significant milestones at its Cedar Psychiatry clinics: administering over 5,000 ketamine treatments and over 2,000 Spravato™ treatments. Launched in 2016, Cedar Psychiatry is a leading provider of innovative, evidence-based mental health therapies in the United States. Clients receiving […]
COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in Canaccord Genuity’s New Paradigms and Treatment Approaches in Mental Health Conference. George Goldsmith, Chairman, CEO and Co‑founder, will deliver the opening day keynote […]
Red Light Holland Announces Closing of $9.77 Million Bought Deal Financing
Red Light Holland Corp. (CSE: TRIP) (“Red Light Holland” or the “Company“), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that it has closed its previously announced bought deal short form prospectus offering, including […]
Field Trip Health Ltd. Common Shares to Trade on the OTCQX Best Market
Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (“FieldTrip”), a leader in the development and delivery of psychedelic therapies, is pleased to announce its common shares have been approved for trading on the OTCQX® Best Market (“OTCQX”) retaining its current symbol FTRPF, effective as of the opening of trading today, January 28, 2021. Field […]
Women in Psychedelics: Building a More Inclusive Industry
The psychedelics industry has become one of the fastest-growing markets in the world as promising research highlights its potential to treat conditions ranging from depression to eating disorders, chronic pain, PTSD, fibromyalgia and beyond. With the FDA onboard, several psychedelics companies have successfully raised capital and are in the process of completing clinical trials designed […]
3 Areas Psychedelics Could Address (and How to Invest in Them)
Psychedelics have shown promise in the treatment of many treatment-resistant conditions, ranging from major depressive disorder to fibromyalgia. The therapeutic markets for these conditions could be worth billions of dollars per year, which has drawn the interest of both researchers and investors across North America. Let’s take a look at three areas where psychedelics […]
Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has received Clinical Trial Authorisation (CTA) from the UK Medicine and Healthcare Products Regulatory Agency (MHRA) to explore the effects of psychedelic agent psilocybin for treating short-lasting unilateral neuralgiform headache attacks (SUNHA), a rare and debilitating headache condition. The upcoming […]
Mydecine Innovations Group Files Application to list to the NASDAQ
DENVER, Jan. 27, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that it has submitted a formal application to list its common shares (“Shares”) […]
NeonMind Appoints Robert Tessarolo as President and Chief Executive Officer
Vancouver, B.C. – January 27, 2021: NeonMind Biosciences Inc. (CSE: NEON) (FSE:6UF) (“NeonMind”), a psychedelic drug development company, is pleased to announce the appointment of accomplished pharmaceutical executive Robert Tessarolo as its President and Chief Executive Officer. Mr. Tessarolo has 25 years of experience in the pharmaceutical industry. Most recently he held the position of President and […]
Psyched Wellness Included in First Psychedelic Exchange Traded Fund
Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (“Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is one of the 17 companies in the United States and Canada that will be included in the first psychedelic exchange-traded fund, which is managed by Horizons ETF Management. […]
Field Trip Health Ltd. (CSE: FTRP, OTCBB: FTRPF) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, announced today the opening of their fifth location in the United States in the city of Atlanta, GA, one of many locations that Field Trip is planning to open in 2021. Located in the […]
Havn Life Sciences Inc. (CNSX:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (“Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it has entered into a definitive agreement (the “Definitive Agreement“) to acquire (the “Acquisition“), on the terms and conditions set forth in the Definitive Agreement, all […]
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) is pleased to announce it has moved out of development and is finalizing its proprietary formulation of all-natural integrative medicines intended to prepare and support patients of psychedelic therapies. MINDCURE’s Mindful Preparation and Mindful Integration pre- and post-treatment supplements are expected […]
Nova Launches Preclinical Autism Spectrum Disorder Therapeutic Study
Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA”) is pleased to announce that it has commenced the diagnostic and treatment phase of its ongoing preclinical model study of autism spectrum disorder (ASD). In this model, which is well accepted by neuroscientists, pregnant rats are exposed to valproic acid (VPA) and the […]
Pure Extracts Enters Into Biomass Purchase Agreements To Support Oil Extract Production
Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, is pleased to announce that it has entered into its first substantial biomass purchase agreements in order to scale-up its production of both THC and CBD extracts. The Company has recently agreed to purchase 220 kgs […]
atai Life Sciences (“atai”), a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced it has entered into a collaboration with Massachusetts General Hospital (“MGH”) and its new initiative, the Center for Neuroscience of Psychedelics, to advance novel mental health treatments through the study of mechanisms underlying the therapeutic […]
Psyence Group to Commence Trading (CSE:PSYG) on January 27, 2021
Psyence Group Inc. (“Psyence”), is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange under the symbol “PSYG” tomorrow, January 27, 2021. The Company is a global platform for innovation leading the way in naturally derived psychedelic therapies and the development and commercialization of related technologies and products. Immediately […]
Englewood Cliffs, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, announced today it has exercised its option to take an exclusive license for […]
Wesana Health Closes $4 Million Convertible Note Round
Wesana Health, an emerging life sciences company committed to patient empowerment and the advancement of psilocybin-based medicine to improve health and wellness, has announced the close of a $4 million convertible note financing round. The company also announced new additions to its senior leadership team. Wesana Health Raises Funds to Enter the Psychedelics Space The […]
Champignon Brands Inc., (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), Chairman and CEO Roger McIntyre today announced the opening of a new Canadian Rapid Treatment Center of Excellence (CRTCE) clinic in Ottawa, Ontario. This third clinic joins the Mississauga and Toronto clinics (CRTCE Clinics) in addressing the unmet need of depression and suicide through novel ketamine […]
Nova Mentis to be Listed in the First-Ever Psychedelic Index
Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that it has been included in the world’s first North American Psychedelic Index. Based on this index, The Horizon Psychedelic Stock Index ETF is expected to commence trading Jan. 27, 2021 under ticker “PSYK” on the […]
PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) (“PharmaDrug“), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, today announced that it has entered into the definitive agreement in respect of the previously announced (see press release dated January 12, 2021) proposed acquisition […]
Novamind to Present at Inaugural KCSA Psychedelics Investor Conference
Novamind Inc. (CSE:NM) (“Novamind”), a mental health company specialized in psychedelic medicine, today announced the Company’s participation at the Psychedelics Investor Conference, hosted by KCSA Strategic Communications on Tuesday, January 26th and Wednesday, January 27th from 9:00 AM – 12:30 PM EST. The two-day event will feature presentations by eminent psychedelics companies and industry leaders. […]
Horizons ETFs to Launch World’s First Psychedelics-Focused ETF
Horizons ETFs Management (Canada) Inc. (“Horizons ETFs“) is pleased to announce that it has filed its final prospectus to launch the Horizons Psychedelic Stock Index ETF (“PSYK“). Units of PSYK have been conditionally approved for listing by the NEO Exchange (“NEO“) and are slated to begin trading on January 27, 2020, under the ticker symbol PSYK:NEO. […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Rob is the co-founding President of Pelorus Equity Group and has more than 18 years of experience in the real estate finance industry. Since the formation of Pelorus in 2010, he has raised more than $175,000,000 in secured real estate transactions. Rob’s primary role at Pelorus Equity Group is the development of strategic alliances with […]
Tim has over 22 years of investment experience as a portfolio manager, asset allocator, and capital markets professional across multiple asset classes, geographies, and platforms. Tim has built and operated two hedge funds, a broker dealer, and raised over $1Bn in capital for his combined businesses. Tim remains a recognized voice within the investment community […]
MediPharm is a pioneer in the cannabis industry as it is the first company in Canada to successfully become a Licensed Producer for cannabis oil production without first receiving a cannabis cultivation license.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
